New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›Mirae Asset Global Investments›203780

203780

Mirae Asset TIGER NASDAQ BIO ETF

Passive ETF Equity

Not rated

The 203780 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: NASDAQ Biotechnology Index. The 203780 ETF provides physical exposure, so by buying it you actually own parts of all the 251 underlying holdings. This share class generates a stream of income by distributing dividends.

₩35,455

+₩160 (+0.45%) today

12:00 AM 08/13/26 Closed

1D price range

₩35,000₩35,455

52W price range

₩22,819.71₩37,545.08

YTD Perf.

+15.85%

YTD Flows

Annualized volatility

Fund AuM

€61M

Share class AuM

€61M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

KR7203780002

TER

0.3%

Inception date

8/27/2014

Issuer

Mirae Asset Global Investments

Benchmark

NASDAQ Biotechnology Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
IBBQ Invesco Nasdaq Biotechnology ETF	+3.74%
BTEC iShares Nasdaq US Biotechnology UCITS ETF	+3.73%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+3.41%
IBB iShares Biotechnology ETF	+4.60%
GNMX Corgi Genomics & Precision Medicine ETF	+5.67%
PBE Invesco Dynamic Biotechnology & Genome ETF	+2.55%
HTEC Robo Global Healthcare Technology and Innovation ETF	+3.77%
DOCG L&G Healthcare Technology & Innovation UCITS ETF	+3.77%
TMED T. Rowe Price Health Care ETF	+2.61%
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	+4.01%
FBT First Trust NYSE Arca Biotechnology ETF	+3.47%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	+4.01%
WDNA WisdomTree BioRevolution UCITS ETF	+5.54%
PJP Invesco Dynamic Pharmaceuticals ETF	+0.21%
2B78 iShares Healthcare Innovation UCITS ETF	+3.64%

API

PerformanceDec 30, 2025 - Aug 12, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

99.76%

Unavailable

0.22%

Latest 203780 news

No content available for this fund

FAQ about 203780

203780 is a Passive ETF. This ETF provides exposure to US Equities.

203780 tracks the NASDAQ Biotechnology Total Return Index - USD, through a full replication replication method.

203780 carries a total expense ratio (TER) of 0.3%, indicating the annual cost for holding the fund.

203780 was introduced to the market on August 27, 2014. It trades on Democratic People's Republic of Korea, among other exchanges

Mirae Asset TIGER NASDAQ BIO ETF, 203780, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.

203780 oversees €61M in assets as of August 12, 2026.

203780 follows a distributing dividend policy, meaning it pays out income to investors. As of August 12, 2026, its 12-month trailing yield was 0.46%.

As of June 30, 2026, 203780 has significant geographic allocations in USA, Netherlands and United Kingdom.

As of June 30, 2026, 203780 focuses largely on Healthcare.

As of June 30, 2026, 203780 holds 251 positions in its portfolio, with 49.15% of assets concentrated in its top 15 holdings.

As of June 30, 2026, 203780 top three holdings include Vertex Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc..

The base currency of 203780 is KRW.

Top 10 holdings

Data as of 06/30/26

Vertex Pharmaceuticals, Inc.

8.17%

Amgen, Inc.

7.83%

Gilead Sciences, Inc.

6.88%

Regeneron Pharmaceuticals, Inc.

4.54%

Revolution Medicines, Inc.

2.86%

Alnylam Pharmaceuticals, Inc.

2.73%

Biogen, Inc.

2.23%

Moderna, Inc.

1.93%

Illumina, Inc.

1.91%

Royalty Pharma Plc

1.77%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

Mirae Asset TIGER NASDAQ BIO ETF

FAQ about 203780

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US